Demonstrates enhanced anticancer peptide prediction using a deep learning framework, highlighting its computational significance.
Introduction Cancer is a leading cause of mortality worldwide. Anticancer peptides (ACPs) are promising therapeutic candidates due to their low toxicity, favorable biocompatibility, and selective anticancer activity; however, experimental ACP identification and screening remain labor-intensive, time-consuming, and costly. Methods We developed ProtT5-MSCRNet, an end-to-end deep learning framework for ACP prediction that integrates ProtT5-based evolutionary representations, multi-scale convolutional feature extraction, channel-wise attention recalibration, and robust optimization strategies. Results Experiments on two independent benchmark datasets showed that ProtT5-MSCRNet outperformed state-of-the-art ACP prediction methods. The model achieved ACC/SN/SP/MCC values of 0.954/0.874/0.983/0.881 on Test Set 1 and 0.984/0.980/0.987/0.967 on Test Set 2. Ablation studies and visualization analyses further supported the effectiveness and interpretability of the proposed model. Discussion ProtT5-MSCRNet provides a robust, accurate, and biologically meaningful computational tool for facilitating ACP identification and accelerating anticancer peptide discovery.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: